Evidence map›Paper›PMID 34786538›Full record

ArticleiScience2021

Screening of COVID-19 cases through a Bayesian network symptoms model and psychophysical olfactory test.

Susana Eyheramendy, Pedro A Saa, Eduardo A Undurraga, Carlos Valencia, Carolina López, Luis Méndez, Javier Pizarro-Berdichevsky, Andrés Finkelstein-Kulka, Sandra Solari, Nicolás Salas and 5 more

Abstract read
In one paragraph

Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Susana EyheramendyFaculty of Engineering and Science, Universidad Adolfo Ibáñez, Santiago, Chile.
Pedro A SaaDepartment of Chemical and Bioprocess Engineering, School of Engineering, Pontificia Universidad Católica de Chile, Santiago, Chile.
Eduardo A UndurragaSchool of Government, Pontificia Universidad Católica de Chile, Santiago, Chile.
Carlos ValenciaCenter for Aromas and Flavors, DICTUC SA., Santiago, Chile.
Carolina LópezCenter for Aromas and Flavors, DICTUC SA., Santiago, Chile.
Luis MéndezEndoscopy Unit, Hospital Padre Hurtado, Santiago, Chile.
Javier Pizarro-BerdichevskyCenter for Innovation in Pelvic Floor, Hospital Sótero del Río, Santiago, Chile.
Andrés Finkelstein-KulkaDepartment of Otolaryngology, Clínica Alemana de Santiago, Santiago, Chile.
Sandra SolariDepartment of Clinical Laboratory, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Nicolás SalasMillennium Institute for Foundational Research on Data (IMFD), Santiago, Chile.
Pedro BahamondesMillennium Institute for Foundational Research on Data (IMFD), Santiago, Chile.
Martín UgarteMillennium Institute for Foundational Research on Data (IMFD), Santiago, Chile.
Pablo BarcelóMillennium Institute for Foundational Research on Data (IMFD), Santiago, Chile.
Marcelo ArenasMillennium Institute for Foundational Research on Data (IMFD), Santiago, Chile.
Eduardo AgosinDepartment of Chemical and Bioprocess Engineering, School of Engineering, Pontificia Universidad Católica de Chile, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sudden loss of smell is among the earliest and most prevalent symptoms of COVID-19 when measured with a clinical psychophysical test. Research has shown the potential impact of frequent screening for olfactory dysfunction, but existing tests are expensive and time consuming. We developed a low-cost ($0.50/test) rapid psychophysical olfactory test (KOR) for frequent testing and a model-based COVID-19 screening framework using a Bayes Network symptoms model. We trained and validated the model on two samples: suspected COVID-19 cases in five healthcare centers (n = 926; 33% prevalence, 309 RT-PCR confirmed) and healthy miners (n = 1,365; 1.1% prevalence, 15 RT-PCR confirmed). The model predicted COVID-19 status with 76% and 96% accuracy in the healthcare and miners samples, respectively (healthcare: AUC = 0.79 [0.75-0.82], sensitivity: 59%, specificity: 87%; miners: AUC = 0.71 [0.63-0.79], sensitivity: 40%, specificity: 97%, at 0.50 infection probability threshold). Our results highlight the potential for low-cost, frequent, accessible, routine COVID-19 testing to support society's reopening.

Indexed as

DiagnosticsDiagnostic technique in health technologyHealth technologyMathematical biosciences

Identifiers

PMID34786538
PMCPMC8580551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.